<span>Application of decentralized clinical trials on AI-focused dermatology</span>
September 1, 2022

Application of decentralized clinical trials on AI-focused dermatology

The use of virtual tools and telecommunications skyrocketed during the COVID-19 pandemic as the world adjusted to new ways of working. In the clinical trials sector, this propelled an increasing adaptation to the decentralized clinical trial (DCT) approach to support research and minimize on-site burden on investigators and patients. With remote mobile device applications and smartphone photography widely accessible, new opportunities to streamline efficiencies and create an enhanced overall experience in dermatology clinical studies abound.
<span>Long COVID Q&A: 4 things to know about COVID cognitive dysfunction</span>
May 24, 2022

Long COVID Q&A: 4 things to know about COVID cognitive dysfunction

Long COVID is a colloquial term used to describe the lingering health symptoms some patients experience after contracting the COVID-19 virus. While the majority of people fully recover from the virus, some “long-hauler” patients report long COVID symptoms ranging from general fatigue to headaches and brain fog, also known as post-COVID cognitive dysfunction. Study of the long-term neurological effects of COVID-19 is a new area of research for neurologists and immunopathologists, and while there are still many unknowns, recent studies have uncovered promising potential biomarkers and diagnostic challenges to consider in the development of new clinical trials.
<span>NfL in Real-World Clinical Settings</span>
November 8, 2022

NfL in Real-World Clinical Settings

Speakers

Dr. Joe Volpe, PhD
Scientific Discipline Director, Labcorp

Dr. Michelle Mielke, PhD
Professor, Epidemiology and Prevention, Wake Forest University School of Medicine

Dr. Asya Wallach, MD
MS Neurologist, Holy Name Medical Center